(603139)"SHAANXI KANGHUI PHARMACEUTICAL CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 603139 · · 15 pages · Chinese
Summary by 6ix AI
The report indicates that the company experienced a decline in net profit attributable to shareholders compared to the previous year. Additionally, the report mentions the establishment of new subsidiaries and the transfer of equity stakes in other companies as part of its strategic initiatives.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Shaanxi Kanghui Pharmaceutical Co., Ltd. on 6ix
Earlier from Shaanxi Kanghui Pharmaceutical
- (603139)"SHAANXI KANGHUI PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 6th Extraordinary General Meeting in 2026
- (603139)"SHAANXI KANGHUI PHARMACEUTICAL CO., LTD."Announcement on Progress in Providing Guarantee for Wholly-owned Subsidiary
- (603139)"SHAANXI KANGHUI PHARMACEUTICAL CO., LTD."Notice on Convening the 6th Extraordinary General Meeting in 2026
- (603139)"SHAANXI KANGHUI PHARMACEUTICAL CO., LTD."Announcement on Supplementing the Estimated Guarantee Amount for Controlled Subsidiaries
- (603139)"SHAANXI KANGHUI PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 17th Meeting of the 6th Board of Directors
Later from Shaanxi Kanghui Pharmaceutical
- (603139)"SHAANXI KANGHUI PHARMACEUTICAL CO., LTD."Announcement on Disposal of Assets
- (603139)"SHAANXI KANGHUI PHARMACEUTICAL CO., LTD."Announcement on Establishment of Wholly-owned Subsidiary
- (603139)"SHAANXI KANGHUI PHARMACEUTICAL CO., LTD."Announcement on Progress of the Computing Power Service Contract of Wholly-owned Subsidiary
- (603139)"SHAANXI KANGHUI PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 19th Meeting of the 6th Board of Directors
Follow Shaanxi Kanghui Pharmaceutical into a list and get an email when it puts out news.
Follow Shaanxi Kanghui Pharmaceutical